Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
Completed · Not applicable · Has a placebo group
Conditions studied: Cocaine Abuse
In brief
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.
Key facts
- Study ID
- NCT00606801
- Run by
- Yale University
- People needed
- 34
- Starts
- 2007-06-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2021-03-15
Who can join
Age: 21 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and females, between the ages 21 and 50
- Fulfill criteria for past cocaine dependence
- No cocaine use for the past 30 days
- No other current dependence or abuse of other drugs or alcohol
- No current medical problems and normal ECG
- Not pregnant,nor breast feeding,
- Using acceptable birth control methods.
You may not qualify if…
- Current major psychiatric illness including mood, psychotic or anxiety disorders
- History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances
- Use of other medications including,drugs that slow heart rate
- Known allergy to galantamine
Where it is running
- Veterans Affairs Hospital — West Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.